Connect with us

Public Companies

Cybin Continues to Expand: Partners with Greenbrook to Open Mental Health Centers in the US

The post Cybin Continues to Expand: Partnership to Open Mental Health Centers in the US appeared first on Microdose.

Cybin has announced an exclusive…

Published

on

The post Cybin Continues to Expand: Partnership to Open Mental Health Centers in the US appeared first on Microdose. Cybin has announced an exclusive research and development collaboration agreement with one of the largest in-person mental health providers in the U.S. Greenbrook – TMS NeuroHealth Centers, a subsidiary of Greenbrook TMS Inc. (TSX:GTMS) (NASDAQ:GBNH) – is a leading provider of in-person treatment of Major Depressive Disorder and other mental health disorders. The company operates 129 outpatient clinics in the U.S. with a focus on Transcranial Magnetic Stimulation (TMS) therapy, an FDA-cleared, non-invasive therapy for depression. Greenbrook has performed over 620,000 TMS treatments to over 17,000 patients with depression. The agreement is for Cybin and Greenbrook to work together to establish Mental Health Centers of Excellence to research and develop innovative psychedelic compound-based therapeutics for patients suffering from depression.  Cybin and Greenbrook will work to develop in-person Centers of Excellence From the press release: The network of outpatient mental health service centers that Greenbrook has built over the years will provide Cybin a leading market advantage to resources and patients that can assist in accelerating clinical study programs in the US as patient access regularly becomes a hurdle in this specific process. According to the Collaboration Agreement, Cybin and Greenbrook will work to develop in-person Centers of Excellence for the following functions:
  • Furthering clinical research of the psychedelic compounds in Cybin’s development pipeline
  • Developing a deeper understanding of psychedelic therapeutic delivery
  • Facilitating recruitment of clinical trial participants for upcoming clinical trials
Cybin seems to have taken an important step in positioning itself as a leader in the future of psychedelic medicine. Drug development and approval is the all-important first step, and these Centers will add crucial in-person research facilities and patient access. But this move also gives Cybin a strong position in the post-approval world. Once drugs are finally approved there will be the task of delivering these new psychedelics to patients at scale, taking into consideration the various bottlenecks of trained therapists, in-person clinics, and patient access. This new relationship between Cybin and Greenbrook provides potential access to one of the largest mental health clinic footprints in the US. When and if Cybin gets a drug approved, this agreement and access to Greenbrook’s clinics could, potentially, put Cybin in an industry-leading position.
Doug Drysdale, Cybin’s CEO: “We are extremely proud and excited to be working with the world-class team at Greenbrook TMS to establish these important Centers of Excellence. This opportunity to combine our pre-clinical and clinical knowledge of psychedelic therapeutics with Greenbrook’s deep experience in patient care and delivery is unparalleled and serves as a major step toward establishing a national distribution network for the future psychedelic therapies.”

Read More

Trending